Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2025-12-25 @ 2:23 AM
NCT ID:
NCT00413634
Eligibility Criteria:
Inclusion Criteria:
* Young patients aged 18-50 years inclusive or Elderly patients aged 65 years and over
* Patients must have a confirmed diagnosis of ET.
* Currently receiving anagrelide hydrochloride at a stable maintenance dose \< 5 mg/day for at least 4 weeks.
Exclusion Criteria:
* Diagnosis of any other myeloproliferative disorder.
* Current use of tobacco in any form (e.g. smoking or chewing)
* Treatment with any known enzyme altering agents (barbiturates, phenothiazines, cimetidine etc.) within 30 days prior to or during the study.
* Patients for whom use of another cytoreductive agent in addition to anagrelide is considered necessary for control of platelet count.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00413634
Study Brief:
Protocol Section:
NCT00413634